Next Article in Journal
Dextran-Curcumin Nanoparticles as a Methotrexate Delivery Vehicle: A Step Forward in Breast Cancer Combination Therapy
Next Article in Special Issue
Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts
Previous Article in Journal
Synthesis and Evaluation of Saccharide-Based Aliphatic and Aromatic Esters as Antimicrobial and Antibiofilm Agents
Previous Article in Special Issue
Libidibia ferrea (jucá), a Traditional Anti-Inflammatory: A Study of Acute Toxicity in Adult and Embryos Zebrafish (Danio rerio)
Article

ZeOncoTest: Refining and Automating the Zebrafish Xenograft Model for Drug Discovery in Cancer

ZeClinics SL, IGTP Edifici Muntanya (c/de Can Ruti, Camí de les Escoles s/n; 08916 BDN, Lab P0-8), 08916 Barcelona, Spain
*
Authors to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(1), 1; https://doi.org/10.3390/ph13010001
Received: 28 September 2019 / Revised: 12 December 2019 / Accepted: 23 December 2019 / Published: 24 December 2019
(This article belongs to the Special Issue Zebrafish as a Powerful Tool for Drug Discovery)
The xenograft of human cancer cells in model animals is a powerful tool for understanding tumor progression and metastatic potential. Mice represent a validated host, but their use is limited by the elevated experimental costs and low throughput. To overcome these restrictions, zebrafish larvae might represent a valuable alternative. Their small size and transparency allow the tracking of transplanted cells. Therefore, tumor growth and early steps of metastasis, which are difficult to evaluate in mice, can be addressed. In spite of its advantages, the use of this model has been hindered by lack of experimental homogeneity and validation. Considering these facts, the aim of our work was to standardize, automate, and validate a zebrafish larvae xenograft assay with increased translatability and higher drug screening throughput. The ZeOncoTest reliability is based on the optimization of different experimental parameters, such as cell labeling, injection site, automated individual sample image acquisition, and analysis. This workflow implementation finally allows a higher precision and experimental throughput increase, when compared to previous reports. The approach was validated with the breast cancer cell line MDA-MB-231, the colorectal cancer cells HCT116, and the prostate cancer cells PC3; and known drugs, respectively RKI-1447, Docetaxel, and Mitoxantrone. The results recapitulate growth and invasion for all tested tumor cells, along with expected efficacy of the compounds. Finally, the methodology has proven useful for understanding specific drugs mode of action. The insights gained bring a step further for zebrafish larvae xenografts to enter the regulated preclinical drug discovery path. View Full-Text
Keywords: zebrafish larvae; cancer; xenograft; drug discovery; automation; throughput zebrafish larvae; cancer; xenograft; drug discovery; automation; throughput
Show Figures

Figure 1

MDPI and ACS Style

Cornet, C.; Dyballa, S.; Terriente, J.; Di Giacomo, V. ZeOncoTest: Refining and Automating the Zebrafish Xenograft Model for Drug Discovery in Cancer. Pharmaceuticals 2020, 13, 1. https://doi.org/10.3390/ph13010001

AMA Style

Cornet C, Dyballa S, Terriente J, Di Giacomo V. ZeOncoTest: Refining and Automating the Zebrafish Xenograft Model for Drug Discovery in Cancer. Pharmaceuticals. 2020; 13(1):1. https://doi.org/10.3390/ph13010001

Chicago/Turabian Style

Cornet, Carles, Sylvia Dyballa, Javier Terriente, and Valeria Di Giacomo. 2020. "ZeOncoTest: Refining and Automating the Zebrafish Xenograft Model for Drug Discovery in Cancer" Pharmaceuticals 13, no. 1: 1. https://doi.org/10.3390/ph13010001

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop